Karyopharm Therapeutics Stock Price. Everything You Need To Know About The Karyopharm Therapeutics Stock!
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company is headquartered in Newton Center, Massachusetts and currently employs 385 full-time employees. The company went IPO on 2013-11-06. The firm is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is evaluating eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.
Karyopharm Therapeutics Stock Price. Everything You Need To Know About The Karyopharm Therapeutics Stock! performance
- Employees 385
- Company HQ Newton Center
- Website https://karyopharm.com/
- KPTI Asset Type Common Stock
- KPTI Market Capitalization 126.9M
- Earnings Per Share -1.25
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth 0
Are you a retail investor from Malaysia, Thailand, Indonesia, or Vietnam looking to invest in the US stock market? Look no further than Karyopharm Therapeutics. As a leading pharmaceutical company, Karyopharm Therapeutics specializes in the development of novel drugs to treat various types of cancers and inflammatory diseases. With Zorion’s investment platform, you can now easily invest in Karyopharm Therapeutics and potentially benefit from their groundbreaking research and development efforts. To make an informed investment decision, Zorion provides investment insights and recommendations to guide you. Additionally, our platform offers access to educational resources and materials to further expand your investment knowledge. Start your investment journey with Karyopharm Therapeutics and Zorion today.
